ArticleJournal of clinical periodontology2026
Surgical Therapy for Peri-Implantitis Using Deproteinised Bovine Bone Mineral With 10% Collagen, Enamel Matrix Derivative and Doxycycline: A Prospective Cohort 10-Year Implant Study.
Article in Journal of clinical periodontology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
aimTo assess 10-year implant survival following surgical management of peri-implantitis using deproteinised bovine bone mineral with 10% collagen (DBBMC), enamel matrix derivative (EMD) and doxycycline powder. MATERIALS AND
methodsThe original population comprised 30 non-smoking, periodontally stable patients (mean age = 44.9 ± 11 years; 64% female; full-mouth plaque and bleeding score < 20%, no bleeding residual periodontal pockets ≥ 4 mm), each with a single peri-implantitis-affected implant (bleeding on probing, probing depth > 6 mm, ≥ 20% radiographic bone loss, implants in function ≥ 2 years). The surgical procedure involved implant surface decontamination with 24% EDTA followed by defect fill with DBBMC/EMD/doxycycline mixture. Patients underwent individualised supportive peri-implant therapy (SPIT) comprising regular clinical monitoring, professional cleaning and antimicrobial protocols for 10 years.
resultsTwenty-nine of the 30 implants survived (96.6% survival rate). Mean probing depth decreased from 8.90 ± 1.9 mm to 3.06 ± 0.98 mm; radiographic bone loss improved from 57% ± 16.5% to 13% ± 2.5%. During 10-year SPIT, 12 implants required adjunctive azithromycin. Fifty-eight percent achieved the successful treatment outcome criterion (SOTC: probing depth < 5 mm, no bone loss 10% from baseline, absence of bleeding on probing/suppuration and recession < 0.5 mm anterior/1.5 mm posterior implants).
conclusionSurgical management of peri-implantitis combined with DBBMC/EMD/doxycycline and personalised SPIT achieved high long-term implant survival and stable clinical outcomes over 10 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.